RS64828B1 - Jedinjenja piridazinona i njihove upotrebe - Google Patents
Jedinjenja piridazinona i njihove upotrebeInfo
- Publication number
- RS64828B1 RS64828B1 RS20231080A RSP20231080A RS64828B1 RS 64828 B1 RS64828 B1 RS 64828B1 RS 20231080 A RS20231080 A RS 20231080A RS P20231080 A RSP20231080 A RS P20231080A RS 64828 B1 RS64828 B1 RS 64828B1
- Authority
- RS
- Serbia
- Prior art keywords
- pyridazinone compounds
- pyridazinone
- compounds
- Prior art date
Links
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical class OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862756553P | 2018-11-06 | 2018-11-06 | |
| PCT/US2019/060157 WO2020097266A1 (en) | 2018-11-06 | 2019-11-06 | Pyridazinone compounds and uses thereof |
| EP19835997.8A EP3877376B1 (en) | 2018-11-06 | 2019-11-06 | Pyridazinone compounds and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS64828B1 true RS64828B1 (sr) | 2023-12-29 |
Family
ID=69160036
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20231080A RS64828B1 (sr) | 2018-11-06 | 2019-11-06 | Jedinjenja piridazinona i njihove upotrebe |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US11091464B2 (sr) |
| EP (2) | EP4248973A3 (sr) |
| JP (2) | JP7162132B2 (sr) |
| KR (1) | KR20210100094A (sr) |
| CN (1) | CN113272291A (sr) |
| AU (1) | AU2019376065A1 (sr) |
| BR (1) | BR112021008905A2 (sr) |
| CA (1) | CA3118934A1 (sr) |
| DK (1) | DK3877376T3 (sr) |
| EA (1) | EA202191084A1 (sr) |
| ES (1) | ES2958954T3 (sr) |
| FI (1) | FI3877376T3 (sr) |
| HR (1) | HRP20231389T1 (sr) |
| HU (1) | HUE063586T2 (sr) |
| IL (1) | IL282998A (sr) |
| LT (1) | LT3877376T (sr) |
| MX (1) | MX2021005350A (sr) |
| PL (1) | PL3877376T3 (sr) |
| PT (1) | PT3877376T (sr) |
| RS (1) | RS64828B1 (sr) |
| SG (1) | SG11202104713RA (sr) |
| SI (1) | SI3877376T1 (sr) |
| WO (1) | WO2020097266A1 (sr) |
| ZA (1) | ZA202103260B (sr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU231285B1 (hu) | 2018-04-18 | 2022-08-28 | Printnet Kereskedelmi És Szolgáltató Kft. | A miozin-2-izoformákat szelektíven gátló, gyógyászatilag hatásos vegyületek |
| BR112021008905A2 (pt) | 2018-11-06 | 2021-08-10 | Edgewise Therapeutics, Inc. | compostos de piridazinona e usos dos mesmos |
| CA3118908A1 (en) * | 2018-11-06 | 2020-05-14 | Edgewise Therapeutics, Inc. | Pyridazinone compounds and uses thereof |
| CA3118904A1 (en) | 2018-11-06 | 2020-05-14 | Edgewise Therapeutics, Inc. | Pyridazinone compounds and uses thereof |
| WO2021231572A1 (en) * | 2020-05-13 | 2021-11-18 | Edgewise Therapeutics, Inc. | Pyridazinone compounds for the treatment of neuromuscular diseases |
| EP4149465A1 (en) * | 2020-05-13 | 2023-03-22 | Edgewise Therapeutics, Inc. | Substituted pyridazinone for use in the treatment of neuromuscular diseases |
| EP4149467A1 (en) * | 2020-05-13 | 2023-03-22 | Edgewise Therapeutics, Inc. | Substituted pyridazinone for use in the treatment of neuromuscular diseases |
| WO2021231630A1 (en) * | 2020-05-13 | 2021-11-18 | Edgewise Therapeutics, Inc. | Substituted pyridazinone for use in the treatment of neuromuscular diseases |
| WO2021231565A1 (en) * | 2020-05-13 | 2021-11-18 | Edgewise Therapeutics, Inc. | Pyridazinone compounds for the treatment of neuromuscular diseases |
| WO2023091606A1 (en) * | 2021-11-17 | 2023-05-25 | Edgewise Therapeutics, Inc. | Pyridazinone compounds and uses thereof |
| WO2023220180A1 (en) * | 2022-05-11 | 2023-11-16 | Edgewise Therapeutics, Inc. | Methods of manufacturing pyridazinone compounds |
| WO2024055007A1 (en) | 2022-09-09 | 2024-03-14 | Edgewise Therapeutics, Inc. | Pyridazinone compositions for the treatment of neuromuscular conditions |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6140270A (ja) | 1984-08-01 | 1986-02-26 | Morishita Seiyaku Kk | ピリダジノン誘導体 |
| DD286354A5 (de) | 1989-08-08 | 1991-01-24 | Karl-Marx-Universitaet Leipzig,De | Verfahren zur herstellung substituierter 2-carbamoyl-methyl-4-phenyl-1,2,5,6-tetrahydro- und 1,2-dihydro-1-oxo-pyridazine |
| ES2131506T3 (es) | 1990-09-21 | 1999-08-01 | Rohm & Haas | Dihidropiridacinonas y piridacinonas como fungicidas. |
| US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| DE69535592T2 (de) | 1994-03-25 | 2008-06-12 | Isotechnika, Inc., Edmonton | Verbesserung der effektivität von arzneimitteln duren deuterierung |
| IL118631A (en) | 1995-06-27 | 2002-05-23 | Tanabe Seiyaku Co | History of pyridazinone and processes for their preparation |
| DE19629817A1 (de) | 1996-07-24 | 1998-01-29 | Hoechst Ag | Neue Imino-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten |
| MXPA02012042A (es) | 2000-06-05 | 2004-08-19 | Altana Pharma Ag | Compuestos efectivos como agonistas de beta-2-adrenorreceptor, y como inhibidores de pde4. |
| RU2328495C2 (ru) | 2003-03-07 | 2008-07-10 | Кова Ко., Лтд. | Производное бензофурана |
| WO2006095666A1 (ja) | 2005-03-07 | 2006-09-14 | Kyorin Pharmaceutical Co., Ltd. | ピラゾロピリジン－４－イルピリダジノン誘導体とその付加塩及びそれらを有効成分とするｐｄｅ阻害剤 |
| WO2007044796A2 (en) | 2005-10-11 | 2007-04-19 | Nps Pharmaceuticals, Inc. | Pyridazinone compounds as calcilytics |
| DE102005057924A1 (de) | 2005-12-05 | 2007-06-06 | Merck Patent Gmbh | Pyridazinonderivate |
| PL2069312T3 (pl) | 2006-07-25 | 2013-03-29 | Cephalon Inc | Pochodne pirydazynonu |
| JP2010519204A (ja) | 2007-02-16 | 2010-06-03 | アムジエン・インコーポレーテツド | 窒素含有複素環ケトン類およびそれらのｃ−Ｍｅｔ阻害薬としての使用 |
| DE102007025718A1 (de) | 2007-06-01 | 2008-12-04 | Merck Patent Gmbh | Pyridazinonderivate |
| DE102007025717A1 (de) | 2007-06-01 | 2008-12-11 | Merck Patent Gmbh | Arylether-pyridazinonderivate |
| DE102007032507A1 (de) | 2007-07-12 | 2009-04-02 | Merck Patent Gmbh | Pyridazinonderivate |
| DE102007038957A1 (de) | 2007-08-17 | 2009-02-19 | Merck Patent Gmbh | 6-Thioxo-pyridazinderivate |
| DE102008019907A1 (de) | 2008-04-21 | 2009-10-22 | Merck Patent Gmbh | Pyridazinonderivate |
| WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| AR081626A1 (es) * | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
| AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
| WO2012021707A2 (en) | 2010-08-11 | 2012-02-16 | The Regents Of The University Of California | Premature-termination-codons readthrough compounds |
| KR101864908B1 (ko) | 2010-09-01 | 2018-06-05 | 질레드 코네티컷 인코포레이티드 | 피리다지논, 그의 제조 방법 및 사용 방법 |
| US8759380B2 (en) | 2011-04-22 | 2014-06-24 | Cytokinetics, Inc. | Certain heterocycles, compositions thereof, and methods for their use |
| CN104144925A (zh) | 2011-10-17 | 2014-11-12 | 拜耳知识产权有限责任公司 | 作为hif抑制剂的取代的噁二唑基吡啶酮和噁二唑基哒嗪酮 |
| CN103570730A (zh) | 2012-08-01 | 2014-02-12 | 中国科学院上海药物研究所 | 具有桥环结构的稠环哒嗪酮类化合物及其制备方法和用途 |
| EP2888256A4 (en) | 2012-08-24 | 2016-02-17 | Univ Texas | HETEROCYCLIC HIF ACTIVITY MODULATORS FOR THE TREATMENT OF DISEASES |
| US9566310B2 (en) * | 2012-09-10 | 2017-02-14 | Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Reno | Methods of treating muscular dystrophy |
| US9216180B2 (en) | 2012-10-02 | 2015-12-22 | New York University | Pharmaceutical compositions and treatment of genetic diseases associated with nonsense mediated RNA decay |
| KR20150096794A (ko) | 2012-12-21 | 2015-08-25 | 제니쓰 에피제네틱스 코포레이션 | 브로모도메인 저해제로서의 신규한 헤테로사이클릭 화합물 |
| WO2014121931A1 (en) | 2013-02-07 | 2014-08-14 | Merck Patent Gmbh | Pyridazinone-amides derivatives |
| CA2906008C (en) | 2013-03-13 | 2019-07-09 | Flatley Discovery Lab, Llc | Pyridazinone compounds and methods for the treatment of cystic fibrosis |
| CN106467495A (zh) | 2015-08-19 | 2017-03-01 | 中国科学院上海药物研究所 | 哒嗪酮类化合物、其制备方法、药物组合物及用途 |
| WO2018081378A1 (en) | 2016-10-26 | 2018-05-03 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for modulating cftr |
| CA3041676A1 (en) * | 2016-10-26 | 2018-05-03 | Daniel Parks | Pyridazine derivatives, compositions and methods for modulating cftr |
| EP3532461A1 (en) | 2016-10-26 | 2019-09-04 | Proteostasis Therapeutics, Inc. | N-phenyl-2-(3-phenyl-6-oxo-1,6-dihydropyridazin-1-yl)acetamide derivatives for treating cystic fibrosis |
| CN110573161A (zh) | 2017-03-28 | 2019-12-13 | 勃林格殷格翰国际有限公司 | 用于治疗肌营养不良的方法的尼达尼布 |
| TW202334101A (zh) | 2017-04-06 | 2023-09-01 | 美商富曼西公司 | 殺真菌之噁二唑 |
| US20180303821A1 (en) | 2017-04-24 | 2018-10-25 | BraneQuest, Inc. | Membrane active molecules |
| BE1025518B1 (fr) | 2017-08-30 | 2019-04-03 | E2 Drives Sa | Groupe motopropulseur |
| EP3700516B1 (en) | 2017-10-27 | 2024-01-24 | Sonic Master Limited | Inhibitors of dux4 induction for regulation of muscle function |
| EP3794151A4 (en) | 2018-05-17 | 2022-03-23 | Bolt Threads, Inc. | SEC-MODIFIED STRAINS FOR IMPROVED SECRETATION OF RECOMBINANT PROTEINS |
| JP2021527636A (ja) | 2018-06-04 | 2021-10-14 | オハイオ・ステイト・イノベーション・ファウンデーション | Ｅａａｔ２活性化因子およびその使用方法 |
| EP3828174A4 (en) | 2018-07-19 | 2022-08-17 | Sumitomo Pharma Co., Ltd. | PYRIDAZINONE DERIVATIVE |
| CN108947912B (zh) | 2018-07-31 | 2021-10-01 | 中国人民解放军总医院 | 一种靶向Neddylation通路的抗肿瘤化合物 |
| CA3118908A1 (en) * | 2018-11-06 | 2020-05-14 | Edgewise Therapeutics, Inc. | Pyridazinone compounds and uses thereof |
| BR112021008905A2 (pt) | 2018-11-06 | 2021-08-10 | Edgewise Therapeutics, Inc. | compostos de piridazinona e usos dos mesmos |
| CA3118904A1 (en) | 2018-11-06 | 2020-05-14 | Edgewise Therapeutics, Inc. | Pyridazinone compounds and uses thereof |
| WO2021231630A1 (en) | 2020-05-13 | 2021-11-18 | Edgewise Therapeutics, Inc. | Substituted pyridazinone for use in the treatment of neuromuscular diseases |
| WO2021231565A1 (en) | 2020-05-13 | 2021-11-18 | Edgewise Therapeutics, Inc. | Pyridazinone compounds for the treatment of neuromuscular diseases |
| EP4149467A1 (en) | 2020-05-13 | 2023-03-22 | Edgewise Therapeutics, Inc. | Substituted pyridazinone for use in the treatment of neuromuscular diseases |
| EP4149465A1 (en) | 2020-05-13 | 2023-03-22 | Edgewise Therapeutics, Inc. | Substituted pyridazinone for use in the treatment of neuromuscular diseases |
| WO2021231572A1 (en) | 2020-05-13 | 2021-11-18 | Edgewise Therapeutics, Inc. | Pyridazinone compounds for the treatment of neuromuscular diseases |
| WO2023091606A1 (en) | 2021-11-17 | 2023-05-25 | Edgewise Therapeutics, Inc. | Pyridazinone compounds and uses thereof |
| WO2024055007A1 (en) | 2022-09-09 | 2024-03-14 | Edgewise Therapeutics, Inc. | Pyridazinone compositions for the treatment of neuromuscular conditions |
-
2019
- 2019-11-06 BR BR112021008905-5A patent/BR112021008905A2/pt unknown
- 2019-11-06 HR HRP20231389TT patent/HRP20231389T1/hr unknown
- 2019-11-06 AU AU2019376065A patent/AU2019376065A1/en active Pending
- 2019-11-06 EP EP23189000.5A patent/EP4248973A3/en active Pending
- 2019-11-06 PL PL19835997.8T patent/PL3877376T3/pl unknown
- 2019-11-06 JP JP2021524227A patent/JP7162132B2/ja active Active
- 2019-11-06 EP EP19835997.8A patent/EP3877376B1/en active Active
- 2019-11-06 CN CN201980088114.7A patent/CN113272291A/zh active Pending
- 2019-11-06 LT LTEPPCT/US2019/060157T patent/LT3877376T/lt unknown
- 2019-11-06 CA CA3118934A patent/CA3118934A1/en active Pending
- 2019-11-06 FI FIEP19835997.8T patent/FI3877376T3/fi active
- 2019-11-06 HU HUE19835997A patent/HUE063586T2/hu unknown
- 2019-11-06 DK DK19835997.8T patent/DK3877376T3/da active
- 2019-11-06 RS RS20231080A patent/RS64828B1/sr unknown
- 2019-11-06 KR KR1020217016684A patent/KR20210100094A/ko unknown
- 2019-11-06 PT PT198359978T patent/PT3877376T/pt unknown
- 2019-11-06 ES ES19835997T patent/ES2958954T3/es active Active
- 2019-11-06 WO PCT/US2019/060157 patent/WO2020097266A1/en active Application Filing
- 2019-11-06 SG SG11202104713RA patent/SG11202104713RA/en unknown
- 2019-11-06 EA EA202191084A patent/EA202191084A1/ru unknown
- 2019-11-06 SI SI201930610T patent/SI3877376T1/sl unknown
- 2019-11-06 MX MX2021005350A patent/MX2021005350A/es unknown
-
2020
- 2020-11-03 US US17/088,469 patent/US11091464B2/en active Active
-
2021
- 2021-05-06 IL IL282998A patent/IL282998A/en unknown
- 2021-05-13 ZA ZA2021/03260A patent/ZA202103260B/en unknown
- 2021-06-11 US US17/345,909 patent/US12012395B2/en active Active
-
2022
- 2022-10-17 JP JP2022166276A patent/JP7429750B2/ja active Active
-
2023
- 2023-09-01 US US18/460,464 patent/US20240025879A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022179796A (ja) | 2022-12-02 |
| SG11202104713RA (en) | 2021-06-29 |
| KR20210100094A (ko) | 2021-08-13 |
| HUE063586T2 (hu) | 2024-01-28 |
| IL282998A (en) | 2021-06-30 |
| EA202191084A1 (ru) | 2021-10-19 |
| PT3877376T (pt) | 2023-09-21 |
| JP7162132B2 (ja) | 2022-10-27 |
| US20210188814A1 (en) | 2021-06-24 |
| ES2958954T3 (es) | 2024-02-16 |
| AU2019376065A1 (en) | 2021-05-27 |
| JP2022506687A (ja) | 2022-01-17 |
| CN113272291A (zh) | 2021-08-17 |
| FI3877376T3 (fi) | 2023-09-26 |
| LT3877376T (lt) | 2023-09-11 |
| CA3118934A1 (en) | 2020-05-14 |
| WO2020097266A1 (en) | 2020-05-14 |
| HRP20231389T1 (hr) | 2024-03-01 |
| EP3877376B1 (en) | 2023-08-23 |
| ZA202103260B (en) | 2023-01-25 |
| PL3877376T3 (pl) | 2024-02-19 |
| EP3877376A1 (en) | 2021-09-15 |
| EP4248973A2 (en) | 2023-09-27 |
| US11091464B2 (en) | 2021-08-17 |
| US20240025879A1 (en) | 2024-01-25 |
| US12012395B2 (en) | 2024-06-18 |
| SI3877376T1 (sl) | 2023-10-30 |
| EP4248973A3 (en) | 2023-12-06 |
| JP7429750B2 (ja) | 2024-02-08 |
| DK3877376T3 (da) | 2023-10-02 |
| MX2021005350A (es) | 2021-08-11 |
| BR112021008905A2 (pt) | 2021-08-10 |
| US20220106291A1 (en) | 2022-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202103260B (en) | Pyridazinone compounds and uses thereof | |
| ZA202103231B (en) | Pyridazinone compounds and uses thereof | |
| IL273236A (en) | Pyrazolopyrimidine compounds and their uses | |
| IL285178A (en) | compounds and their use | |
| GB201803568D0 (en) | Novel compounds and uses | |
| IL285177A (en) | compounds and their use | |
| GB201714745D0 (en) | New compounds and uses | |
| IL277502A (en) | Compounds and uses for them | |
| GB201714740D0 (en) | New compounds and uses | |
| IL286497A (en) | compounds and their use | |
| GB201714734D0 (en) | New compounds and uses | |
| IL279483A (en) | Cyanotriazole compounds and their uses | |
| IL291499A (en) | Azaquinoline compounds and their uses | |
| IL284764A (en) | compounds and their uses | |
| IL280644A (en) | Magnesium serine compound and its use | |
| GB201714736D0 (en) | New compounds and uses | |
| IL285118A (en) | compounds and their uses | |
| GB201812078D0 (en) | Novel compounds and their uses | |
| GB201712110D0 (en) | New compounds and uses | |
| GB201801102D0 (en) | New compounds and uses | |
| IL280369A (en) | Myokines and their uses | |
| GB201806349D0 (en) | New compounds and uses | |
| ZA202201239B (en) | Aminothiolester compounds and uses thereof | |
| GB201810667D0 (en) | New compounds and uses | |
| IL283540A (en) | Dock1 inhibitory compound and use thereof |